Compare Schwab US Large Cap Growth ETF (SCHG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Schwab US Large Cap Growth ETFTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Schwab US Large Cap Growth ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Schwab US Large Cap Growth ETF trades at $35.07, while State Street SPDR S&P Biotech ETF trades at $159.61. Which is the better fit depends on your goals.

	SCHG	XBI
Sector	Sector/Thematic	Broad Market / Factor
52-Week High	$35.94	$169.55
52-Week Low	$28.10	$93.43

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Schwab US Large Cap Growth ETF

SCHG trades at $35.25, down 0.79% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on large-cap U.S. growth stocks, offering broad exposure at a low cost. Recent news highlights its competitive positioning against peers like QQQM and VUG, with historical performance showing strong long-term returns.

The outlook for SCHG is positive due to its growth-oriented portfolio and cost efficiency, though concentration in top holdings and market volatility pose risks. Investor sentiment is mixed, with some analysts favoring alternatives like GARP strategies for better valuation and fundamentals.

State Street SPDR S&P Biotech ETF

XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

SCHG

SCHG preferred over QQQM for broader growth exposure and lower cost, while QQQM suits pure Nasdaq-100 focus.Seeking Alpha · 1 day agoBullish View details →

XBI

Biotech ETF IBB outperformed S&P 500 by 22 points in 3 months amid pharma patent cliff deals.24/7 Wall Street · 2 days agoBullish State Street SPDR S&P Biotech ETF (XBI) rated Buy with 8%-14% returns expected despite prior 76% rallySeeking Alpha · 5 days agoBullish View details →

About Schwab US Large Cap Growth ETF

SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.